Full-Time

Vice President Commercial Strategy

Posted on 5/23/2026

Evotec

Evotec

1,001-5,000 employees

Global drug-discovery services via partnerships

No salary listed

Hamburg, Germany

In Person

Category
Business & Strategy (2)
,
Required Skills
Financial Modeling
Requirements
  • Bachelor’s or Master’s degree in Business, Life Sciences, or related discipline; MBA or advanced business qualification preferred
  • 6-8 years of experience in commercial strategy, corporate strategy, or business development within the CRO, CDMO, biotech, or pharma sector
  • Proven track record of developing and executing commercial strategies that drive growth and profitability in a science-based business environment
  • Strong understanding of the drug discovery and development value chain and the dynamics of CRO and integrated R&D partnerships
  • Experience in portfolio design, pricing models, and offer structuring (standalone, integrated, strategic alliances)
  • Exceptional analytical, financial modeling, and strategic communication skills
  • Ability to influence senior stakeholders and lead cross-functional teams in a matrix environment
Responsibilities
  • Partner with the SVP, Commercial Strategy, and segment leadership to define and execute the segment’s commercial strategy in alignment with Evotec’s corporate priorities and growth ambitions
  • Translate Evotec’s strategic pillars into actionable business plans and commercial objectives for the respective segment
  • Support the development of the annual and long-range business plans, including revenue, margin, and market expansion goals
  • Identify growth opportunities in target therapeutic areas, client segments, and geographies
  • Shape the commercial offering portfolio across standalone CRO services, integrated end-to-end R&D solutions (“Integrated Discovery” and “Integrated Development”), and long-term strategic alliances
  • Collaborate with scientific, business development, and operations teams to define differentiated value propositions, pricing frameworks, and delivery models for each offer type
  • Support design and packaging of modular offerings that enable flexibility for clients while maximizing Evotec’s operational leverage
  • Drive commercial readiness for new service capabilities or technology platforms, ensuring alignment between market needs and internal capacity
  • Lead commercial performance tracking for the CRO segment, analyzing revenue mix, client profitability, and pipeline conversion metrics
  • Partner with Finance and Operations to model scenarios and assess commercial levers influencing margin improvement
  • Develop performance dashboards and insights to inform data-driven strategic decision-making
  • Identify underperforming areas and develop recovery or optimization strategies
  • Monitor CRO market trends, client needs, and competitor strategies to inform Evotec’s commercial positioning and offering evolution
  • Provide forward-looking insights on emerging technologies (e.g., AI-driven drug discovery, data platforms, modality shifts) that could enhance Evotec’s value proposition
  • Support market segmentation and targeting strategies to focus resources on high-value opportunities
  • Act as the bridge between Operations, Business Development, Finance, and the central Commercial Strategy function, ensuring strong strategic alignment and execution consistency
  • Partner with BD teams to refine go-to-market approaches, pricing strategies, and client engagement models
  • Support the SVP and CRO leadership in strategic projects such as portfolio prioritization, partnership models, and commercial process optimization
  • Prepare and deliver strategic presentations, business cases, and performance reviews for executive and board-level discussions
  • Contribute to internal communication of the CRO commercial strategy, ensuring clarity and alignment across regions and functions
Desired Qualifications
  • MBA or advanced business qualification preferred

Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hamburg, Germany

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • J.Train expands beyond Sandoz into higher-margin recurring biologics manufacturing contracts.
  • Horizon restructuring targets €75 million structural savings by end-2027.
  • New CFO Claire Hinshelwood and COO Ingrid Müller sharpen execution and capital allocation.

What critics are saying

  • Q1 2026 revenue fell 21.7%, showing persistent softness in core discovery demand.
  • Horizon restructuring books €75 million charges and delays savings until 2027.
  • Sandoz concentration exposes Just-Evotec Biologics to customer leverage and order volatility.

What makes Evotec unique

  • Evotec combines drug discovery, biologics manufacturing, and AI platforms across modalities.
  • Just-Evotec Biologics commercializes continuous manufacturing through J.Train, validated by Sandoz.
  • Evotec serves all Top 20 pharma and 800-plus biotechs globally.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Evotec who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 8th, 2026
Evotec delivers $67M cost savings and $650M Sandoz deal amid 1.1% revenue decline

Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.

The Associated Press
Apr 7th, 2026
Evotec nominates Dieter Weinand as supervisory board chairman to drive commercial execution

Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.

The Associated Press
Apr 1st, 2026
Evotec appoints Dr. Ashiq H. Khan as chief commercial officer with $7B+ deal track record

Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.

The Associated Press
Mar 19th, 2026
Evotec receives $10M milestone from Bristol Myers Squibb for kidney cancer drug trial

Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.

Yahoo Finance
Mar 16th, 2026
Evotec unveils "Horizon" plan with $85M savings, 800 job cuts and 10-site footprint by 2028

Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.